Universe Pharmaceuticals (NASDAQ:UPC) Stock Price Up 0.7% – What’s Next?

Universe Pharmaceuticals INC (NASDAQ:UPC) shares rose 0.7% during mid-day trading on Wednesday . The stock traded as high as $3.00 and last traded at $2.91. Approximately 40,949 shares traded hands during trading, a decline of 87% from the average daily volume of 309,696 shares. The stock had previously closed at $2.89.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Universe Pharmaceuticals in a research note on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Universe Pharmaceuticals presently has an average rating of “Sell”.

Universe Pharmaceuticals Stock Up 0.7%

The company has a 50 day moving average of $3.04 and a two-hundred day moving average of $3.36.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.